cognitive behavioural therapy for menopausal symptoms

Conditions: Menopausal Depression

Summary: this study examined the effectiveness of a new cognitive-behavioural therapy for menopausal symptoms (cbt-meno). half of participants were randomly assigned to the 12-week cbt-meno program and half to a 12-week waitlist. common menopause symptoms (i.e., hot flashes/night sweats, depression, anxiety, poor sleep, and sexual concerns) were assessed at baseline, 12-weeks post-baseline, and (for women in the cbt-meno condition) at 3-month follow-up.

women going through the menopausal transition often experience adverse physical changes (e.g., hot flashes/night sweats, sleep difficulties, sexual concerns) in addition to emotional difficulties (e.g., depression, anxiety) that can significantly impact functioning and overall quality of life. to date, hormone therapy (ht) has been the most commonly used treatment to relieve symptoms of menopause. however, reports have questioned the safety of ht long-term (e.g., risk of heart attacks, strokes, cancer) for some women. cognitive-behavioural therapy (cbt), has been proposed as a low-risk treatment for menopausal symptoms. the investigators developed a comprehensive non-pharmacological, cbt for menopausal symptoms (cbt-meno), published the treatment manual (green, mccabe, \& soares, 2012), and obtained initial evidence supporting the effectiveness of cbt-meno in a single-sample pilot study (green et al., 2013). the goal in the study reported here was to conduct a larger randomized controlled trial to evaluate the effectiveness of the cbt-meno program compared to a waitlist condition. the investigators hypothesized that participants would experience less intense/disruptive hot flashes/night sweats, reduced depression and anxiety, improvement in sleep difficulties, and sexual concerns. the investigators also predicted that these benefits would be maintained at 3-month follow-up and that participants would report high treatment satisfaction.

Eligibility criteria:
inclusion criteria: 1. menopausal staging: perimenopause or postmenopausal as per straw definitions (harlow et al., 2012) or having surgically-induced menopause 2. a minimum of mild level of severity of depressive symptoms (defined by the beck depression inventory, scores of 14 or greater during initial screen), 3. significant vasomotor symptoms: i.e., vasomotor symptoms that are (a) frequent (≥ 4 hot flashes per day/night or 21 or more per week); (b) distressing (≥ 3 or more on the vasomotor subscale of the greene climacteric scale); and (c) interfering (≥ 30 or greater on the hot flash related daily interference scale). 4. not taking hormonal, anti-depressant, or any herbal therapies or if taking these medications they must be taking a stable dose for at least three months prior to the study and for the duration of the study, 5. speak, read, and write in english sufficiently to comprehend testing procedures and written materials in group treatment. exclusion criteria: 1. participants who are severely depressed/suicidal at the time of the screen or intake assessment that would warrant acute treatment and hence, render them unable to act as a wait list control participant if randomized to this condition, 2. participants with psychotic disorders, or current substance dependence.

Keywords: vasomotor symptoms